Investor Presentation H1 2023
50
Investor presentation
First six months of 2023
PIONEER PLUS achieved its primary endpoint and demonstrated
statistically significant HbA1c reduction vs oral sema 14 mg
Oral semaglutide 25 mg and 50 mg vs 14 mg in subjects with T2D
Oral semaglutide 50 mg
R
Oral semaglutide 25 mg
1:1:1
Oral semaglutide 14 mg
68 weeks
5 weeks
follow-up
Inclusion criteria (1,606 participants):
Primary endpoint:
Change from baseline to week 52 in
HbA1c
Secondary endpoint:
.
Type 2 Diabetes
• HbA1c 8.0 - 10.5%
Change from baseline (%)
Headline trial results
Change in HbA1c
Change in body weight
Mean baseline HbA1c: 9.0%
Mean baseline body weight: 96.4 kg
-1.5%
-1.9%*
-2.2%*
Change from baseline (kg)
-4.5
-7.0*
-9.2*
.
Change from baseline to week 52 in
body weight
BMI ≥25 kg/m²
Stable dose of 1-3 OADS
(metformin, SU, SGLT-2i or DPP-411)
All doses of oral semaglutide appeared to have safe and well-tolerated profile
Oral semaglutide 14 mg Oral semaglutide 50mg
Oral semaglutide 25mg
*Statistically significant/superior vs oral semaglutide 14 mg; 1DPP-4i terminated at randomization
T2D: Type 2 diabetes; HbA1c: Glycated haemoglobin; BMI: Body Mass Index; OADS: Oral antidiabetic drugs; SU: Sulfonylurea; SGLT-2i; Sodium-glucose cotransporter-2 inhibitors; DPP-4i: dipeptidyl peptidase-4 inhibitors
Note: Trial product estimands shown; Trial objective: To compare the safety and efficacy of 25 and 50 mg oral semaglutide with 14 mg oral semaglutide once daily in people with type 2 diabetes
Novo NordiskⓇView entire presentation